Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 29471-29480 Newer>

Financial Advisor April 2008 Jeff Schlegel	Carnival For Investors Brazil vaults to the top spot on the MSCI Emerging Markets index as the biggest emerging market opportunity in the world.
Financial Advisor April 2008 Eric Uhlfelder	Bank Shares Near Bargain Levels It wasn't all that long ago that bank stocks rocked. However, by the beginning of 2008, banking shares had collapsed. Is it time to start buying them again?
BusinessWeek March 27, 2008 Dean Foust	The BW 50 Management vision that spurns conventional wisdom is one trait many companies on the BusinessWeek 50 list share. This year's rankings are also our most international to date.
BusinessWeek March 27, 2008	How the 50 Made the Cut To identify the companies on the BW 50, we first focused on two core financial measures: average return on capital and growth.
BusinessWeek March 27, 2008 Judith Crown	How Coach Defies the Odds Even in a time of near recession, the luxury accessory maker is going strong through a mix of high-end and outlet stores, and steady innovation.
BusinessWeek March 27, 2008 Dean Foust	Vetting the BW 50's Investment Potential The companies that make the BusinessWeek 50 are truly a cut above the rest when it comes to their operating performance, but how do these companies fare as investments? It's a good question. The answer: It depends.
The Motley Fool April 2, 2008 Rich Duprey	The Short Case for Origin Agritech Origin Agritech manufacturers genetically modified corn, rice, cotton, and canola seeds in China. Much can go right for this company, but, much can also go wrong.
The Motley Fool April 2, 2008 Tom Hutchinson	UBS: You Hang In There The Swiss bank looks to cut its losses and put the crisis behind it.
The Motley Fool April 2, 2008 Toby Shute	A Treasure Trove for Trina? Integrated alternate energy company Trina Solar announces a big polysilicon supply deal with an outfit called GCL Silicon Technology.
The Motley Fool April 2, 2008 Michael P. Cecil	Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite.
<Older 29471-29480 Newer> Return to current articles.